EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network’s Laboratory External Quality Assessment Programme, 2014–2019

David Litt, Mary P E Slack, Tomoka Nakamura, Steve Gray, Shila Seaton, Elizabeth J Fagan, Carmen Sheppard, Jason M Mwenda, Gloria Rey-Benito, Amany Ghoniem, Dovile Videbaek, Emanuel Tondo und 2 weitere

Journal of Medical Microbiology · 2023

DOI: 10.1099/jmm.0.001644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2023. Verfasst von David Litt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory and Vaccine Preventable Bacteria Reference Unit, United Kingdom Health Security Agency (formerly Public Health England), London, UK. Hauptthemen laut MEDLINE: Vaccine-Preventable Diseases, Meningitis, Bacterial, Neisseria meningitidis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In 2009, the World Health Organization (WHO) established the Global Invasive Bacterial Vaccine Preventable Disease (IB-VPD) Surveillance Network (GISN) to monitor the global burden and aetiology of bacterial meningitis, pneumonia and sepsis caused by Haemophilus influenzae (Hi), Neisseria meningitidis (Nm) and Streptococcus pneumoniae (Sp). Hypothesis/Gap Statement . The GISN established an external quality assessment (EQA) programme for the characterization of Hi, Nm and Sp by culture and diagnostic PCR.

Aim

To assess the performance of sentinel site laboratories (SSLs), national laboratories (NLs) and regional reference laboratories (RRLs) between 2014 and 2019 in the EQA programme. Methodology. Test samples consisted of bacterial smears for Gram-staining, viable isolates for identification and serotyping or serogrouping (ST/SG), plus simulated cerebrospinal fluid (CSF) samples for species detection and ST/SG by PCR. SSLs and NLs were only required to analyse the slides for Gram staining and identify the species of the live isolates. RRLs, and any SLs and NLs that had the additional laboratory capacity, were also required to ST/SG the viable isolates and analyse the simulated CSF samples.

Results

Across the period, 69–112 SS/NL labs and eight or nine RRLs participated in the EQA exercise. Most participants correctly identified Nm and Sp in Gram-stained smears but were less successful with Hi and other species. SSLs/NLs identified the Hi, Nm and Sp cultures well and also submitted up to 56 % of Hi, 62 % of Nm and 33 % of Sp optional ST/SG results each year. There was an increasing trend in the proportion of correct results submitted over the 6 years for Nm and Sp. Some SSLs/NLs also performed the optional detection and ST/SG of the three organisms by PCR in simulated CSF from 2015 onwards; 89–100 % of the CSF samples were correctly identified and 76–93 % of Hi-, 90–100 % of Nm- and 75–100 % of Sp-positive samples were also correctly ST/SG across the distributions. The RRLs performed all parts of the EQA to a very high standard, with very few errors across all aspects of the EQA.

Conclusion

The EQA has been an important tool in maintaining high standards of laboratory testing and building of laboratory capacity in the GISN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine-Preventable DiseasesMeningitis, BacterialNeisseria meningitidisHumansLaboratoriesStreptococcus pneumoniaeHaemophilus influenzaeReal-Time Polymerase Chain ReactionWorld Health OrganizationGentian VioletPhenazines

Stichwörter der Autor:innen

EQAHaemophilus influenzaeNeisseria meningitidisStreptococcus pneumoniaeWHOWorld Health Organizationexternal quality assessment

Substanzen

Gram's stainGentian VioletPhenazines

Autor:innen und Institutionen

  • Respiratory and Vaccine Preventable Bacteria Reference Unit, United Kingdom Health Security Agency (formerly Public Health England), London, UK.
  • World Health Organization Collaborating Centre for Haemophilus influenzae and Streptococcus pneumoniae, United Kingdom Health Security Agency (formerly Public Health England), London, UK.
  • School of Medicine & Dentistry, Griffith University Gold Coast Campus, Queensland 4222, Australia.
  • Present address: Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • Present address: Nagasaki University, Tropical Medicine and Global Health, Nagasaki, Japan.
  • Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Förderung

  • World Health Organization

Zitieren

APA

Litt, D., Slack, M. P. E., Nakamura, T., Gray, S., Seaton, S., Fagan, E. J., Sheppard, C., Mwenda, J. M., Rey-Benito, G., Ghoniem, A., Videbaek, D., Tondo, E., Grabovac, V., & Serhan, F. (2023). Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network’s Laboratory External Quality Assessment Programme, 2014–2019. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001644

Vancouver

Litt D, Slack MPE, Nakamura T, Gray S, Seaton S, Fagan EJ, et al. Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network’s Laboratory External Quality Assessment Programme, 2014–2019. Journal of Medical Microbiology. 2023. doi:10.1099/jmm.0.001644

BibTeX
@article{Litt2023,
  author = {Litt, David and Slack, Mary P E and Nakamura, Tomoka and Gray, Steve and Seaton, Shila and Fagan, Elizabeth J and Sheppard, Carmen and Mwenda, Jason M and Rey-Benito, Gloria and Ghoniem, Amany and Videbaek, Dovile and Tondo, Emanuel and Grabovac, Varja and Serhan, Fatima},
  title = {Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network’s Laboratory External Quality Assessment Programme, 2014–2019},
  journal = {Journal of Medical Microbiology},
  year = {2023},
  doi = {10.1099/jmm.0.001644}
}
Kostenlos starten →